Article
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
International immunopharmacology - 1 Nov 2022
Zheng Jiaxi, Shao Minghai, Yang Weifang, Ren Justin, Chen Xiaofeng, Yang Haihua
Abstract excerpt
OBJECTIVES: To investigate the clinical benefits of combination therapy with immune checkpoint inhibitors (ICIs) and best combination regimen for people with advanced hepatocellular carcinoma (HCC) and to explore the predictive performance of tumour mutation burden (TMB). METHODS: We conducted a systematic literature search to identify clinical trials. Meta-analysis and subgroup analyses were performed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.